Related Experiment Video
Updated: May 16, 2026
12:12
In vivo Reprogramming of Adult Somatic Cells to Pluripotency by Overexpression of Yamanaka Factors
Published on: December 17, 2013
In vivo HSC gene therapy enables sustained eCD4-Ig expression for SIV prevention.
Chang Li1, Anna K Anderson1, Anne-Sophie Kuhlmann2
1Department of Medicine, Division of Medical Genetics, University of Washington, Seattle, WA 98195, USA.
Molecular Therapy. Advances
|May 15, 2026
Summary
This study developed an in vivo hematopoietic stem cell (HSC) gene therapy using helper-dependent adenovirus (HDAd) vectors to deliver a decoy protein for HIV-1 prevention. The therapy showed promise in macaques by reducing viral reservoirs and viral loads.
Area of Science:
- Gene Therapy
- Virology
- Immunology
Background:
- Developing effective HIV-1 prevention strategies remains critical.
- Hematopoietic stem cell (HSC) gene therapy offers a potential route for durable treatment.
- Existing therapies face challenges in long-term efficacy and accessibility.
Purpose of the Study:
- To engineer an in vivo HSC gene therapy for HIV-1 prevention and control.
- To utilize helper-dependent adenovirus (HDAd) 6/3+ vectors for direct in vivo HSC transduction.
- To evaluate the efficacy of secreting a decoy protein (eCD4-Ig) for viral neutralization.
Main Methods:
- Engineered HDAd 6/3+ vectors to deliver an enhanced eCD4-Ig variant (eCD4-Ig-Emm06).
- Transduced HSCs in vivo in rhesus macaques.
- Assessed long-term expression, differentiation, trafficking, and neutralization efficacy of eCD4-Ig-Emm06.
- Quantified viral reservoirs and plasma viral loads in treated animals.
Main Results:
- Achieved long-term expression of eCD4-Ig-Emm06 from transduced HSCs in rhesus macaques.
- Transduced HSCs differentiated into lymphoid and myeloid lineages, with B cells as a key source of eCD4-Ig-Emm06.
- HDAd-eCD4Ig-Emm06 treatment led to reduced splenic viral reservoirs and lower plasma viral loads.
- One animal with high eCD4Ig-Emm06 levels showed fewer founder viruses and delayed viremia onset.
Conclusions:
- Validated HDAd 6/3+ as a platform for durable gene-based delivery of biologics.
- Demonstrated proof-of-concept for in vivo HSC gene therapy in controlling HIV-1 infection.
- Identified strategies for improving protective efficacy, including lineage-specific expression and reduced immunogenicity.
Keywords:
HIVSIVeCD4-Iggene therapyhelper-dependent adenovirus vectorshematopoietic stem cellsin vivomobilizationrhesus macaquesMore Related Videos
Related Concept Videos
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...